The study is testing the incidence of MACE and incidence of renal events between Ozempic® users and users with other anti-diabetic medications in T2D patients. This is a retrospective study, and participants had received Ozempic or any other anti-diabetic medications.
Study Type
OBSERVATIONAL
Enrollment
100,000
NIS- Tianjin Medical University Chu Hsien-I Memorial Hospital-Department of Endocrinology
Tianjin, Tianjin Municipality, China
Time to 3P major adverse cardiovascular events
Measured in days.
Time frame: From index date to the first composite 3P MACE (stroke, myocardial infarction, all-cause death) event or censoring event (up to 36 months)
Time to 5P MACE
Measured in days.
Time frame: From index date to the first composite 5P MACE (stroke, myocardial infarction, all-cause death, heart failure hospitalization, coronary revascularization) event or censoring event (up to 36 months)
Time to stroke
Measured in days.
Time frame: From index date to the first stroke event or censoring event (up to 36 months)
Time to myocardial infarction (MI)
Measured in days.
Time frame: From index date to the first MI event or censoring event (up to 36 months)
Time to heart failure (HF)
Measured in days.
Time frame: From index date to the first HF event or censoring event (up to 36 months)
Time to composite renal event
Measured in days.
Time frame: From index date to first composite renal (kidney failure: dialysis/transplantation/eGFR <15, ≥50% eGFR reduction from baseline, or kidney-related/cardiovascular death) or censoring event (up to 36 months)
Time to renal disease-related hospitalization
Measured in days.
Time frame: From index date to the first renal disease-related hospitalization or censoring event (up to 36 months)
Incidence rate of 3P MACE
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Measured in Percentage, per 1000 patient year.
Time frame: From index date to the first composite 3P MACE (stroke, myocardial infarction, all-cause death) event or censoring event (up to 36 months)
Incidence rate of 5P MACE
Measured in Percentage, per 1000 patient year.
Time frame: From index date to the first composite 5P MACE (stroke, myocardial infarction, all-cause death, heart failure hospitalization, coronary revascularization) event or censoring event (up to 36 months)
Incidence rate of stroke
Measured in Percentage, per 1000 patient year.
Time frame: From index date to the first stroke event or censoring event (up to 36 months)
Incidence rate of myocardial infarction
Measured in Percentage, per 1000 patient year.
Time frame: From index date to the first MI event or censoring event (up to 36 months)
Incidence rate of heart failure
Measured in Percentage, per 1000 patient year.
Time frame: From index date to the first HF event or censoring event (up to 36 months)
Incidence rate of composite renal event
Measured in Percentage, per 1000 patient year.
Time frame: From index date to first composite renal (kidney failure: dialysis/transplantation/eGFR <15, ≥50% eGFR reduction from baseline, or kidney-related/cardiovascular death) or censoring event (up to 36 months)
Incidence rate of renal disease-related hospitalization
Measured in Percentage, per 1000 patient year.
Time frame: From index date to the first renal disease-related hospitalization or censoring event (up to 36 months)
Proportion of days covered (PDC) in 6 months
Measured in percentage.
Time frame: From index date to Day 180
PDC in 12 months
Measured in percentage.
Time frame: From index date to Day 360